{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:27:58Z","timestamp":1792074478925,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00259-015-3027-4","type":"journal-article","created":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T09:24:05Z","timestamp":1426152245000},"page":"1144-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?"],"prefix":"10.1007","volume":"42","author":[{"given":"Prasanna","family":"Santhanam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Chandramahanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruszniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"key":"3027_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000033","volume":"21","author":"MA Lewis","year":"2014","unstructured":"Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2014;21:22\u20137. doi: 10.1097\/MED.0000000000000033 .","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"3027_CR2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","volume":"331","author":"Y Jiao","year":"2011","unstructured":"Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199\u2013203. doi: 10.1126\/science.1200609 .","journal-title":"Science"},{"key":"3027_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","volume":"146","author":"I Marinoni","year":"2014","unstructured":"Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146:453\u201360. doi: 10.1053\/j.gastro.2013.10.020 .","journal-title":"Gastroenterology"},{"key":"3027_CR4","doi-asserted-by":"crossref","first-page":"E2404","DOI":"10.1073\/pnas.1319962111","volume":"111","author":"R Ohki","year":"2014","unstructured":"Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, et al. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A. 2014;111:E2404\u201313. doi: 10.1073\/pnas.1319962111 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3027_CR5","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1172\/JCI67963","volume":"123","author":"MS Banck","year":"2013","unstructured":"Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013;123:2502\u20138. doi: 10.1172\/JCI67963 .","journal-title":"J Clin Invest"},{"key":"3027_CR6","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/ERC-12-0338","volume":"20","author":"A Karpathakis","year":"2013","unstructured":"Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: cracking the epigenetic code. Endocr Relat Cancer. 2013;20:R65\u201382. doi: 10.1530\/erc-12-0338 .","journal-title":"Endocr Relat Cancer"},{"key":"3027_CR7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/MPA.0b013e3182152bda","volume":"40","author":"A Nasir","year":"2011","unstructured":"Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, et al. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011;40:627\u201333. doi: 10.1097\/MPA.0b013e3182152bda .","journal-title":"Pancreas"},{"key":"3027_CR8","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/cncr.24180","volume":"115","author":"I Drozdov","year":"2009","unstructured":"Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, et al. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer. 2009;115:1638\u201350. doi: 10.1002\/cncr.24180 .","journal-title":"Cancer"},{"key":"3027_CR9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00330-012-2615-y","volume":"23","author":"P Bhosale","year":"2013","unstructured":"Bhosale P, Shah A, Wei W, Varadhachary G, Johnson V, Shah V, et al. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol. 2013;23:400\u20137. doi: 10.1007\/s00330-012-2615-y .","journal-title":"Eur Radiol"},{"key":"3027_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.dld.2013.09.021","volume":"46","author":"H Helgadottir","year":"2014","unstructured":"Helgadottir H, Metz DC, Yang YX, Rhim AD, Bjornsson ES. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis. 2014;46:125\u201330. doi: 10.1016\/j.dld.2013.09.021 .","journal-title":"Dig Liver Dis"},{"key":"3027_CR11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157\u201376. doi: 10.1159\/000335597 .","journal-title":"Neuroendocrinology"},{"key":"3027_CR12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","volume":"39","author":"DS Klimstra","year":"2010","unstructured":"Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707\u201312. doi: 10.1097\/MPA.0b013e3181ec124e .","journal-title":"Pancreas"},{"key":"3027_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ctrv.2011.03.002","volume":"37","author":"A Stoyianni","year":"2011","unstructured":"Stoyianni A, Pentheroudakis G, Pavlidis N. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Cancer Treat Rev. 2011;37:358\u201365. doi: 10.1016\/j.ctrv.2011.03.002 .","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 1","key":"3027_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000051853","volume":"62","author":"B Eriksson","year":"2000","unstructured":"Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62 Suppl 1:33\u20138. doi: 10.1159\/000051853 .","journal-title":"Digestion"},{"key":"3027_CR15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.dld.2014.07.004","volume":"46","author":"A Frilling","year":"2014","unstructured":"Frilling A, Smith G, Clift AK, Martin J. Capsule endoscopy to detect primary tumour site in metastatic neuroendocrine tumours. Dig Liver Dis. 2014;46:1038\u201342. doi: 10.1016\/j.dld.2014.07.004 .","journal-title":"Dig Liver Dis"},{"key":"3027_CR16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/MCG.0b013e318281a44e","volume":"47","author":"DJ Cangemi","year":"2013","unstructured":"Cangemi DJ, Patel MK, Gomez V, Cangemi JR, Stark ME, Lukens FJ. Small bowel tumors discovered during double-balloon enteroscopy: analysis of a large prospectively collected single-center database. J Clin Gastroenterol. 2013;47:769\u201372. doi: 10.1097\/MCG.0b013e318281a44e .","journal-title":"J Clin Gastroenterol"},{"key":"3027_CR17","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1097\/RLU.0000000000000447","volume":"40","author":"V Ambrosini","year":"2015","unstructured":"Ambrosini V, Campana D, Nanni C, Marzola MC, Rubello D, Fanti S. 68Ga DOTANOC PET\/CT detects primary malignant insulinoma. Clin Nucl Med. 2015;40:e132\u20133. doi: 10.1097\/RLU.0000000000000447 .","journal-title":"Clin Nucl Med"},{"key":"3027_CR18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00259-014-2943-z","volume":"42","author":"A Imperiale","year":"2015","unstructured":"Imperiale A, Sebag F, Vix M, Castinetti F, Kessler L, Moreau F, et al. F-FDOPA PET\/CT imaging of insulinoma revisited. Eur J Nucl Med Mol Imaging. 2015;42:409\u201318. doi: 10.1007\/s00259-014-2943-z .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/PAS.0b013e31824aba59","volume":"36","author":"ES Chan","year":"2012","unstructured":"Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol. 2012;36:737\u201343. doi: 10.1097\/PAS.0b013e31824aba59 .","journal-title":"Am J Surg Pathol"},{"key":"3027_CR20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","volume":"12","author":"F Panzuto","year":"2005","unstructured":"Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083\u201392. doi: 10.1677\/erc.1.01017 .","journal-title":"Endocr Relat Cancer"},{"key":"3027_CR21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.sla.0000164073.08093.5d","volume":"241","author":"JP Boudreaux","year":"2005","unstructured":"Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg. 2005;241:839\u201345; discussion 845\u20136.","journal-title":"Ann Surg"},{"key":"3027_CR22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jamcollsurg.2013.12.035","volume":"218","author":"JP Boudreaux","year":"2014","unstructured":"Boudreaux JP, Wang YZ, Diebold AE, Frey DJ, Anthony L, Uhlhorn AP, et al. A single institution\u2019s experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors. J Am Coll Surg. 2014;218:837\u201344. doi: 10.1016\/j.jamcollsurg.2013.12.035 .","journal-title":"J Am Coll Surg"},{"key":"3027_CR23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00268-002-6630-z","volume":"26","author":"P Hellman","year":"2002","unstructured":"Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26:991\u20137. doi: 10.1007\/s00268-002-6630-z .","journal-title":"World J Surg"},{"key":"3027_CR24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","volume":"140","author":"B Givi","year":"2006","unstructured":"Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140:891\u20137; discussion 897\u20138. doi: 10.1016\/j.surg.2006.07.033 .","journal-title":"Surgery"},{"key":"3027_CR25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1067\/msy.2002.128615","volume":"132","author":"JM Sarmiento","year":"2002","unstructured":"Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery. 2002;132:976\u201382; discussion 982\u20133. doi: 10.1067\/msy.2002.128615 .","journal-title":"Surgery"},{"key":"3027_CR26","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1245\/s10434-012-2462-8","volume":"19","author":"S Gaujoux","year":"2012","unstructured":"Gaujoux S, Gonen M, Tang L, Klimstra D, Brennan MF, D\u2019Angelica M, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19:4270\u20137. doi: 10.1245\/s10434-012-2462-8 .","journal-title":"Ann Surg Oncol"},{"key":"3027_CR27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","volume":"39","author":"JP Boudreaux","year":"2010","unstructured":"Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010;39:753\u201366. doi: 10.1097\/MPA.0b013e3181ebb2a5 .","journal-title":"Pancreas"},{"key":"3027_CR28","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/bjs.8842","volume":"99","author":"G Capurso","year":"2012","unstructured":"Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg. 2012;99:1480\u20136. doi: 10.1002\/bjs.8842 .","journal-title":"Br J Surg"},{"key":"3027_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/lt.500010208","volume":"1","author":"B Dousset","year":"1995","unstructured":"Dousset B, Houssin D, Soubrane O, Boillot O, Baudin F, Chapuis Y. Metastatic endocrine tumors: is there a place for liver transplantation? Liver Transpl Surg. 1995;1:111\u20137.","journal-title":"Liver Transpl Surg"},{"key":"3027_CR30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514\u201323. doi: 10.1056\/NEJMoa1009290 .","journal-title":"N Engl J Med"},{"key":"3027_CR31","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005\u201312. doi: 10.1016\/s0140-6736(11)61742-x .","journal-title":"Lancet"},{"key":"3027_CR32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333. doi: 10.1056\/NEJMoa1316158 .","journal-title":"N Engl J Med"},{"key":"3027_CR33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501\u201313. doi: 10.1056\/NEJMoa1003825 .","journal-title":"N Engl J Med"},{"key":"3027_CR34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.thorsurg.2014.04.005","volume":"24","author":"L Bodei","year":"2014","unstructured":"Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, et al. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac Surg Clin. 2014;24:333\u201349. doi: 10.1016\/j.thorsurg.2014.04.005 .","journal-title":"Thorac Surg Clin"},{"key":"3027_CR35","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-14-0488","volume":"172","author":"WA Zwan van der","year":"2015","unstructured":"van der Zwan WA, Bodei L, Mueller-Brand J, de Herder W, Kvols L, Kwekkeboom D. GEP-NETS update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172:R1\u20138. doi: 10.1530\/eje-14-0488 .","journal-title":"Eur J Endocrinol"},{"key":"3027_CR36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(06)70801-4","volume":"7","author":"KP Koopmans","year":"2006","unstructured":"Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728\u201334. doi: 10.1016\/S1470-2045(06)70801-4 .","journal-title":"Lancet Oncol"},{"key":"3027_CR37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.220.2.r01au25373","volume":"220","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001;220:373\u201380. doi: 10.1148\/radiology.220.2.r01au25373 .","journal-title":"Radiology"},{"key":"3027_CR38","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1210\/jc.2008-1349","volume":"94","author":"F Montravers","year":"2009","unstructured":"Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab. 2009;94:1295\u2013301. doi: 10.1210\/jc.2008-1349 .","journal-title":"J Clin Endocrinol Metab"},{"key":"3027_CR39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","volume":"40","author":"S Balogova","year":"2013","unstructured":"Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40:943\u201366. doi: 10.1007\/s00259-013-2342-x .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR40","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1210\/jc.2013-1942","volume":"98","author":"A Imperiale","year":"2013","unstructured":"Imperiale A, Addeo P, Averous G, Namer IJ, Bachellier P. Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on 18F-FDOPA PET\/CT. J Clin Endocrinol Metab. 2013;98:2643\u20134. doi: 10.1210\/jc.2013-1942 .","journal-title":"J Clin Endocrinol Metab"},{"key":"3027_CR41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET\/CT. Eur J Nucl Med Mol Imaging. 2013;40:514\u201323. doi: 10.1007\/s00259-012-2309-3 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/RLU.0b013e3182485110","volume":"37","author":"H Jacobsson","year":"2012","unstructured":"Jacobsson H, Larsson P, Jonsson C, Jussing E, Gryback P. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med. 2012;37:362\u20135. doi: 10.1097\/RLU.0b013e3182485110 .","journal-title":"Clin Nucl Med"},{"key":"3027_CR43","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s002590100639","volume":"28","author":"M Hofmann","year":"2001","unstructured":"Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751\u20137. doi: 10.1007\/s002590100639 .","journal-title":"Eur J Nucl Med"},{"key":"3027_CR44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00259-004-1697-4","volume":"32","author":"D Wild","year":"2005","unstructured":"Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724. doi: 10.1007\/s00259-004-1697-4 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR45","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508\u201318.","journal-title":"J Nucl Med"},{"key":"3027_CR46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/RLU.0b013e31823ea730","volume":"37","author":"N Naswa","year":"2012","unstructured":"Naswa N, Sharma P, Kumar A, Soundararajan R, Kumar R, Malhotra A, et al. 68Ga-DOTANOC PET\/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med. 2012;37:245\u201351. doi: 10.1097\/RLU.0b013e31823ea730 .","journal-title":"Clin Nucl Med"},{"key":"3027_CR47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"V Prasad","year":"2010","unstructured":"Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET\/CT. Eur J Nucl Med Mol Imaging. 2010;37:67\u201377. doi: 10.1007\/s00259-009-1205-y .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00006231-200405000-00004","volume":"25","author":"G Savelli","year":"2004","unstructured":"Savelli G, Lucignani G, Seregni E, Marchiano A, Serafini G, Aliberti G, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun. 2004;25:445\u20139.","journal-title":"Nucl Med Commun"},{"key":"3027_CR49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1245\/s10434-014-3981-2","volume":"22","author":"H Ilhan","year":"2015","unstructured":"Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, et al. Impact of 68Ga-DOTATATE PET\/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol. 2015;22:164\u201371. doi: 10.1245\/s10434-014-3981-2 .","journal-title":"Ann Surg Oncol"},{"key":"3027_CR50","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00259-007-0476-4","volume":"34","author":"A Hubalewska-Dydejczyk","year":"2007","unstructured":"Hubalewska-Dydejczyk A, Kulig J, Szybinski P, Mikolajczak R, Pach D, Sowa-Staszczak A, et al. Radio-guided surgery with the use of [99mTc-EDDA\/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract. Eur J Nucl Med Mol Imaging. 2007;34:1545\u201355. doi: 10.1007\/s00259-007-0476-4 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR51","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2967\/jnumed.114.144543","volume":"55","author":"EC Etchebehere","year":"2014","unstructured":"Etchebehere EC, de Oliveira SA, Gumz B, Vicente A, Hoff PG, Corradi G, et al. 68Ga-DOTATATE PET\/CT, 99mTc-HYNIC-octreotide SPECT\/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med. 2014;55:1598\u2013604. doi: 10.2967\/jnumed.114.144543 .","journal-title":"J Nucl Med"},{"key":"3027_CR52","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/RLU.0000000000000533","volume":"39","author":"J Kunikowska","year":"2014","unstructured":"Kunikowska J, Pawlak D, Kolasa A, Mikolajczak R, Krolicki L. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET\/CT uptake by primary site-dependent neuroendocrine tumor metastasis. Clin Nucl Med. 2014;39:855\u201361. doi: 10.1097\/rlu.0000000000000533 .","journal-title":"Clin Nucl Med"},{"key":"3027_CR53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s13139-013-0258-9","volume":"48","author":"TH Tan","year":"2014","unstructured":"Tan TH, Lee BN, Hassan SZ. Diagnostic value of 68Ga-DOTATATE PET\/CT in liver metastases of neuroendocrine tumours of unknown origin. Nucl Med Mol Imaging. 2014;48:212\u20135. doi: 10.1007\/s13139-013-0258-9 .","journal-title":"Nucl Med Mol Imaging"},{"key":"3027_CR54","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","volume":"252","author":"A Frilling","year":"2010","unstructured":"Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850\u20136. doi: 10.1097\/SLA.0b013e3181fd37e8 .","journal-title":"Ann Surg"},{"key":"3027_CR55","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s12149-014-0856-3","volume":"28","author":"O Alonso","year":"2014","unstructured":"Alonso O, Rodriguez-Taroco M, Savio E, Bentancourt C, Gambini JP, Engler H. 68Ga-DOTATATE PET\/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. Ann Nucl Med. 2014;28:638\u201345. doi: 10.1007\/s12149-014-0856-3 .","journal-title":"Ann Nucl Med"},{"key":"3027_CR56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5603\/NMR.2011.0004","volume":"14","author":"G Lapinska","year":"2011","unstructured":"Lapinska G, Bryszewska M, Fijolek-Warszewska A, Kozlowicz-Gudzinska I, Ochman P, Sackiewicz-Slaby A. The diagnostic role of 68Ga-DOTATATE PET\/CT in the detection of neuroendocrine tumours. Nucl Med Rev Cent East Eur. 2011;14:16\u201320.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"3027_CR57","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","volume":"40","author":"H Geijer","year":"2013","unstructured":"Geijer H, Breimer LH. Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770\u201380. doi: 10.1007\/s00259-013-2482-z .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR58","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cen.12566","volume":"81","author":"P Santhanam","year":"2014","unstructured":"Santhanam P, Taieb D. Role of 18F-FDOPA PET\/CT imaging in endocrinology. Clin Endocrinol. 2014;81:789\u201398. doi: 10.1111\/cen.12566 .","journal-title":"Clin Endocrinol"},{"key":"3027_CR59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2967\/jnumed.113.126896","volume":"55","author":"A Imperiale","year":"2014","unstructured":"Imperiale A, Rust E, Gabriel S, Detour J, Goichot B, Duclos B, et al. 18F-fluorodihydroxyphenylalanine PET\/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J Nucl Med. 2014;55:367\u201372. doi: 10.2967\/jnumed.113.126896 .","journal-title":"J Nucl Med"},{"key":"3027_CR60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"Haug A, Auernhammer CJ, Wangler B, Tiling R, Schmidt G, Goke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765\u201370. doi: 10.1007\/s00259-008-1030-8 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR61","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","volume":"35","author":"V Ambrosini","year":"2008","unstructured":"Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431\u20138. doi: 10.1007\/s00259-008-0769-2 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR62","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","volume":"112","author":"I Kayani","year":"2008","unstructured":"Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447\u201355. doi: 10.1002\/cncr.23469 .","journal-title":"Cancer"},{"key":"3027_CR63","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2967\/jnumed.114.142224","volume":"55","author":"DH Simsek","year":"2014","unstructured":"Simsek DH, Kuyumcu S, Turkmen C, Sanli Y, Aykan F, Unal S, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET\/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med. 2014;55:1811\u20137. doi: 10.2967\/jnumed.114.142224 .","journal-title":"J Nucl Med"},{"key":"3027_CR64","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","volume":"55","author":"H Bahri","year":"2014","unstructured":"Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786\u201390. doi: 10.2967\/jnumed.114.144386 .","journal-title":"J Nucl Med"},{"key":"3027_CR65","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2967\/jnumed.114.137166","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Adler L, Sabet A, Poppel TD, Grabellus F, Yuce A, et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260\u20136. doi: 10.2967\/jnumed.114.137166 .","journal-title":"J Nucl Med"},{"key":"3027_CR66","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s00259-014-2850-3","volume":"41","author":"P Sharma","year":"2014","unstructured":"Sharma P, Naswa N, Kc SS, Alvarado LA, Dwivedi AK, Yadav Y, et al. Comparison of the prognostic values of 68Ga-DOTANOC PET\/CT and 18F-FDG PET\/CT in patients with well-differentiated neuroendocrine tumor. Eur J Nucl Med Mol Imaging. 2014;41:2194\u2013202. doi: 10.1007\/s00259-014-2850-3 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3027_CR67","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10585-014-9672-3","volume":"31","author":"D Kaemmerer","year":"2014","unstructured":"Kaemmerer D, Posorski N, von Eggeling F, Ernst G, Horsch D, Baum RP, et al. The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm. Clin Exp Metastasis. 2014;31:817\u201327. doi: 10.1007\/s10585-014-9672-3 .","journal-title":"Clin Exp Metastasis"},{"key":"3027_CR68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2967\/jnumed.114.145029","volume":"56","author":"S Surti","year":"2015","unstructured":"Surti S. Update on time-of-flight PET imaging. J Nucl Med. 2015;56:98\u2013105. doi: 10.2967\/jnumed.114.145029 .","journal-title":"J Nucl Med"},{"key":"3027_CR69","author":"H Hu","year":"2015","unstructured":"Hu H, Cao X, Kang F, Wang M, Lin Y, Liu M, et al. Feasibility study of novel endoscopic Cerenkov luminescence imaging system in detecting and quantifying gastrointestinal disease: first human results. Eur Radiol. 2015. doi: 10.1007\/s00330-014-3574-2 .","journal-title":"Eur Radiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-015-3027-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3027-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:06:24Z","timestamp":1558699584000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-015-3027-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3027"],"URL":"https:\/\/doi.org\/10.1007\/s00259-015-3027-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,13]]}}}